Company intelligence / Profile preview

Modulari-T

Ownership: Private
Development stage: Other

Overview

Modulari-T is developing the MARC platform, a next-generation modular immune receptor technology designed to overcome key limitations of current CAR-T therapies. Preclinical data suggest MARC-engineered cells are twice as potent as standard CAR-T cells in tumor clearance and exhibit significantly reduced side effects and immune exhaustion. The company is currently advancing through preclinical validation with ambitions for clinical trials in oncology, with future expansion into autoimmunity and regenerative medicine.

Therapeutic areas: ImmunologyOncology
Modalities: Cell therapyGene therapyChimeric antigen receptor T cell therapy (CAR-T)Synthetic biology-based therapies
Industry: Biotech

Drug pipeline

2 assets

uPAR-MARC

Preclinical

1 more asset in the full pipeline.

Partnerships

Y Combinator participant/cohort memberDistrict 3 Innovation Center support/incubation

Beyond the preview

Go deeper on Modulari-T.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Modulari-T.